Combined Oral Contraceptive Use and the Risk of Cervical Cancer: Literature Review

Nenhuma Miniatura disponível
Citações na Scopus
0
Tipo de produção
article
Data de publicação
2023
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
GEORG THIEME VERLAG KG
Autores
BOVO, Adriane Cristina
PEDRAO, Priscila Grecca
GUIMARAES, Yasmin Medeiros
GODOY, Luani Rezende
RESENDE, Julio Cesar Possati
REIS, Ricardo dos
Citação
REVISTA BRASILEIRA DE GINECOLOGIA E OBSTETRICIA, v.45, n.12, p.E818-E823, 2023
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Cervical cancer (CC) is caused by persistent infection of human papillomavirus of high oncogenic risk (hr-HPV); however, several cofactors are important in its carcinogenesis, such as smoking, multiparity, and prolonged use of oral hormonal contraceptives (COCs). Worldwide, 16% of women use COCs, whereas in Brazil this rate is of similar to 30%. The safety and adverse effects of COCs are widely discussed in the literature, including the increase in carcinogenic risk. Due to the existence of several drugs, combinations, and dosages of COCs, it is hard to have uniform information in epidemiological studies. Our objective was to perform a narrative review on the role of COCs use in the carcinogenesis of cervical cancer. Several populational studies have suggested an increase in the incidence of cervical cancer for those who have used COCs for > 5 years, but other available studies reach controversial and contradictory results regarding the action of COCs in the development of CC.
Palavras-chave
Oral hormonal contraceptives, Cervical cancer, HPV
URI
https://observatorio.fm.usp.br/handle/OPI/58082
Referências
  1. Anastasiou E, 2022, CONTRACEPTION, V107, P1, DOI 10.1016/j.contraception.2021.10.018
  2. [Anonymous], 1985, Br Med J (Clin Res Ed), V290, P961
  3. [Anonymous], 1999, IARC Monogr Eval Carcinog Risks Hum, V72, P49
  4. [Anonymous], 1979, IARC Monogr Eval Carcinog Risk Chem Hum, V21, P11
  5. [Anonymous], 2019, Contraceptive Use by Method 2019: Data Booklet (ST/ESA/SER.A/435)
  6. Appleby P, 2007, LANCET, V370, P1609, DOI 10.1016/S0140-6736(07)61684-5
  7. Arbeit JM, 1996, P NATL ACAD SCI USA, V93, P2930, DOI 10.1073/pnas.93.7.2930
  8. Asthana S, 2020, EUR J OBSTET GYN R B, V247, P163, DOI 10.1016/j.ejogrb.2020.02.014
  9. Beral V, 1999, BRIT MED J, V318, P96, DOI 10.1136/bmj.318.7176.96
  10. BERRY G, 1993, INT J CANCER, V55, P228
  11. Brake T, 2005, P NATL ACAD SCI USA, V102, P2490, DOI 10.1073/pnas.0409883102
  12. Castellsagué X, 2006, JNCI-J NATL CANCER I, V98, P303, DOI 10.1093/jnci/djj067
  13. Castellsagué X, 2008, GYNECOL ONCOL, V110, pS4, DOI 10.1016/j.ygyno.2008.07.045
  14. Castle PE, 2005, INT J CANCER, V117, P1007, DOI 10.1002/ijc.21279
  15. CdPe Vigilancia, 2022, incidencia de cancer no Brasil, P160
  16. Chung SH, 2008, CANCER RES, V68, P9928, DOI 10.1158/0008-5472.CAN-08-2051
  17. Doorbar J, 2012, VACCINE, V30, pF55, DOI 10.1016/j.vaccine.2012.06.083
  18. Dragoman MV, 2014, BEST PRACT RES CL OB, V28, P825, DOI 10.1016/j.bpobgyn.2014.06.003
  19. Gierisch JM, 2013, CANCER EPIDEM BIOMAR, V22, P1931, DOI 10.1158/1055-9965.EPI-13-0298
  20. HILDESHEIM A, 1990, INT J CANCER, V45, P860, DOI 10.1002/ijc.2910450513
  21. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2012, IARC Monogr Eval Carcinog Risks Hum, V100, P1
  22. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2007, IARC Monogr Eval Carcinog Risks Hum, V91, P1
  23. Iversen L, 2017, AM J OBSTET GYNECOL, V216, DOI 10.1016/j.ajog.2017.02.002
  24. Kamani M, 2022, ECANCERMEDICALSCIENC, V16, DOI 10.3332/ecancer.2022.1416
  25. KHOO SK, 1986, MED J AUSTRALIA, V144, P185, DOI 10.5694/j.1326-5377.1986.tb128354.x
  26. Kjellberg L, 2000, BRIT J CANCER, V82, P1332, DOI 10.1054/bjoc.1999.1100
  27. LaVecchia C, 1996, DRUG SAFETY, V14, P260, DOI 10.2165/00002018-199614040-00006
  28. Longatto A, 2011, GYNECOL OBSTET INVES, V71, P93, DOI 10.1159/000320742
  29. Moodley J, 2004, CURR OPIN OBSTET GYN, V16, P27, DOI 10.1097/00001703-200402000-00006
  30. Moodley M, 2003, INT J GYNECOL CANCER, V13, P103, DOI 10.1136/ijgc-00009577-200303000-00001
  31. Moreno V, 2002, LANCET, V359, P1085, DOI 10.1016/S0140-6736(02)08150-3
  32. Muñoz N, 2002, LANCET, V359, P1093, DOI 10.1016/S0140-6736(02)08151-5
  33. NEGRINI BP, 1990, CANCER RES, V50, P4670
  34. Peng YH, 2017, J OBSTET GYNAECOL RE, V43, P913, DOI 10.1111/jog.13291
  35. PETITTI DB, 1992, CONTRACEPTION, V45, P93, DOI 10.1016/0010-7824(92)90043-S
  36. PRENTICE RL, 1987, ADV CANCER RES, V49, P285, DOI 10.1016/S0065-230X(08)60801-5
  37. Rana MJ, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0205927
  38. Roura E, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147029
  39. SCHLESSELMAN JJ, 1995, OBSTET GYNECOL, V85, P793, DOI 10.1016/0029-7844(95)00022-J
  40. Sedgh G, 2014, STUD FAMILY PLANN, V45, P301, DOI 10.1111/j.1728-4465.2014.00393.x
  41. Siegel RL, 2023, CA-CANCER J CLIN, V73, P17, DOI 10.3322/caac.21763
  42. Smith JS, 2003, LANCET, V361, P1159, DOI 10.1016/S0140-6736(03)12949-2
  43. SPERLING MA, 1975, WESTERN J MED, V122, P42
  44. SWAN SH, 1982, AM J EPIDEMIOL, V115, P10, DOI 10.1093/oxfordjournals.aje.a113264
  45. SWAN SH, 1979, NEW ENGL J MED, V301, P46
  46. Syrjänen K, 2006, ANTICANCER RES, V26, P4729
  47. THOMAS DB, 1978, CANCER RES, V38, P3991
  48. VESSEY MP, 1983, LANCET, V2, P930
  49. Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F
  50. WILLIAMS RS, 1992, POSTGRAD MED, V92, P155
  51. WRIGHT NH, 1978, BRIT J CANCER, V38, P273, DOI 10.1038/bjc.1978.198

Coleções
Artigos e Materiais de Revistas Científicas - FM/Outros
Artigos e Materiais de Revistas Científicas - LIM/14
Artigos e Materiais de Revistas Científicas - ODS/03